Page 1 of 132
NR-546 ADVANCED PHARMACOLOGY: PSYCHOPHARMACOLOGY
FOR THE PMHNP EXAM 2026 QUESTIONS WITH VERIFIED
QUESTIONS DETAILED RATIONALES GRADED A+
NR-546 Advanced Pharmacology: Psychopharmacology for the PMHNP — Comprehensive
Exam Preparation
Summarized 10-Point Exam Coverage
1. Neurobiology and Neurotransmission — Neuronal structure, synaptic transmission, action
potential propagation, and the role of major neurotransmitter systems (dopamine, serotonin,
norepinephrine, GABA, glutamate, acetylcholine) in psychiatric disorders. Key dopaminergic
pathways: mesolimbic (positive symptoms), mesocortical (negative/cognitive symptoms),
nigrostriatal (EPS), and tuberoinfundibular (prolactin regulation).
2. Pharmacokinetics and Pharmacodynamics — Absorption, distribution, metabolism (CYP450
enzymes), excretion, half-lives, steady-state, receptor affinity, intrinsic activity, dose-response
relationships, and therapeutic index. Emphasis on drug-drug interactions and individual
variability.
3. Antidepressants — SSRIs, SNRIs, MAOIs, TCAs, and atypical agents: mechanisms of action,
FDA indications, side effect profiles, black box warnings, discontinuation syndrome, serotonin
syndrome, and clinical selection strategies.
4. Mood Stabilizers — Lithium, valproate, lamotrigine, and carbamazepine: therapeutic ranges,
toxicity management, teratogenic risks, drug interactions, and monitoring parameters including
renal, thyroid, and hematologic function.
,Page 2 of 132
5. Anxiolytics and Hypnotics — Benzodiazepines, buspirone, and non-benzodiazepine
hypnotics: GABA-A receptor pharmacology, dependence and withdrawal, buspirone's 5-HT1A
partial agonist mechanism, and clinical distinctions in onset and side effect profiles.
6. Antipsychotics — First-generation (typical) and second-generation (atypical) agents: D2 vs.
D2/5-HT2A receptor blockade, extrapyramidal symptoms, tardive dyskinesia, metabolic
syndrome, QT prolongation, neuroleptic malignant syndrome, and clozapine's agranulocytosis
monitoring requirements.
7. ADHD Medications — Stimulants (methylphenidate, amphetamines) and non-stimulants
(atomoxetine, guanfacine, clonidine): mechanisms, dosing strategies, side effects (appetite
suppression, cardiovascular effects), abuse potential, and FDA-approved pediatric and adult
indications.
8. Special Populations — Pregnancy and lactation considerations, pediatric and geriatric dosing,
hepatic and renal impairment adjustments, teratogenic risk categories, and cultural
considerations in psychopharmacology.
9. Adverse Effects and Toxicity Management — Recognition and management of serotonin
syndrome, neuroleptic malignant syndrome, lithium toxicity, Stevens-Johnson syndrome,
hypertensive crisis with MAOIs, anticholinergic toxidrome, and agranulocytosis.
10. Integrated Clinical Decision-Making — Treatment algorithms for major depressive disorder,
bipolar disorder, schizophrenia, generalized anxiety disorder, ADHD, and substance use
disorders. Emphasis on evidence-based sequencing, augmentation strategies, and personalized
medicine.
Questions with Rationales
,Page 3 of 132
Section 1: Neurobiology and Neurotransmission (Questions 1–25)
Q1. A 24-year-old neuroscience student is studying the propagation of action potentials along a
myelinated axon. Which structural feature is primarily responsible for the rapid, saltatory
conduction observed in myelinated neurons?
A. Nodes of Ranvier, where myelin is absent and voltage-gated sodium channels are densely
concentrated
B. The myelin sheath itself, which contains voltage-gated sodium channels that depolarize in
sequence
C. Schwann cell nuclei, which generate local electrical currents that propagate the action
potential
D. The axonal microtubules, which physically transport the depolarization wave via dynein-
mediated conduction
Correct Answer: A
Rationale: Saltatory conduction occurs because the myelin sheath electrically insulates
internodal segments, forcing depolarization to regenerate only at the Nodes of Ranvier, where
voltage-gated Na⁺ channels cluster densely. This reduces membrane capacitance and increases
resistance across internodes, producing conduction velocities up to 50× faster than
unmyelinated fibers.
, Page 4 of 132
Q2. A patient with schizophrenia demonstrates prominent positive symptoms that respond to
D2 antagonist antipsychotics. Overactivity in which dopaminergic pathway is most directly
implicated in the pathophysiology of these positive symptoms?
A. Nigrostriatal pathway, projecting from the substantia nigra pars compacta to the dorsal
striatum
B. Mesolimbic pathway, projecting from the ventral tegmental area (VTA) to the nucleus
accumbens and limbic structures
C. Mesocortical pathway, projecting from the VTA to the prefrontal cortex
D. Tuberoinfundibular pathway, projecting from the arcuate nucleus of the hypothalamus to the
pituitary stalk
Correct Answer: B
Rationale: The mesolimbic pathway mediates reward and incentive motivation, and its
hyperactivity is the canonical dopaminergic abnormality underlying positive psychotic
symptoms. The nigrostriatal pathway governs movement, the mesocortical pathway governs
cognition and negative symptoms, and the tuberoinfundibular pathway regulates prolactin
secretion.
Q3. A PMHNP is explaining the mechanism of dopaminergic signaling to a medical student. The
presynaptic neuron releases dopamine into the synaptic cleft, where it binds to postsynaptic
receptors. The primary mechanism for terminating this dopamine signal is:
NR-546 ADVANCED PHARMACOLOGY: PSYCHOPHARMACOLOGY
FOR THE PMHNP EXAM 2026 QUESTIONS WITH VERIFIED
QUESTIONS DETAILED RATIONALES GRADED A+
NR-546 Advanced Pharmacology: Psychopharmacology for the PMHNP — Comprehensive
Exam Preparation
Summarized 10-Point Exam Coverage
1. Neurobiology and Neurotransmission — Neuronal structure, synaptic transmission, action
potential propagation, and the role of major neurotransmitter systems (dopamine, serotonin,
norepinephrine, GABA, glutamate, acetylcholine) in psychiatric disorders. Key dopaminergic
pathways: mesolimbic (positive symptoms), mesocortical (negative/cognitive symptoms),
nigrostriatal (EPS), and tuberoinfundibular (prolactin regulation).
2. Pharmacokinetics and Pharmacodynamics — Absorption, distribution, metabolism (CYP450
enzymes), excretion, half-lives, steady-state, receptor affinity, intrinsic activity, dose-response
relationships, and therapeutic index. Emphasis on drug-drug interactions and individual
variability.
3. Antidepressants — SSRIs, SNRIs, MAOIs, TCAs, and atypical agents: mechanisms of action,
FDA indications, side effect profiles, black box warnings, discontinuation syndrome, serotonin
syndrome, and clinical selection strategies.
4. Mood Stabilizers — Lithium, valproate, lamotrigine, and carbamazepine: therapeutic ranges,
toxicity management, teratogenic risks, drug interactions, and monitoring parameters including
renal, thyroid, and hematologic function.
,Page 2 of 132
5. Anxiolytics and Hypnotics — Benzodiazepines, buspirone, and non-benzodiazepine
hypnotics: GABA-A receptor pharmacology, dependence and withdrawal, buspirone's 5-HT1A
partial agonist mechanism, and clinical distinctions in onset and side effect profiles.
6. Antipsychotics — First-generation (typical) and second-generation (atypical) agents: D2 vs.
D2/5-HT2A receptor blockade, extrapyramidal symptoms, tardive dyskinesia, metabolic
syndrome, QT prolongation, neuroleptic malignant syndrome, and clozapine's agranulocytosis
monitoring requirements.
7. ADHD Medications — Stimulants (methylphenidate, amphetamines) and non-stimulants
(atomoxetine, guanfacine, clonidine): mechanisms, dosing strategies, side effects (appetite
suppression, cardiovascular effects), abuse potential, and FDA-approved pediatric and adult
indications.
8. Special Populations — Pregnancy and lactation considerations, pediatric and geriatric dosing,
hepatic and renal impairment adjustments, teratogenic risk categories, and cultural
considerations in psychopharmacology.
9. Adverse Effects and Toxicity Management — Recognition and management of serotonin
syndrome, neuroleptic malignant syndrome, lithium toxicity, Stevens-Johnson syndrome,
hypertensive crisis with MAOIs, anticholinergic toxidrome, and agranulocytosis.
10. Integrated Clinical Decision-Making — Treatment algorithms for major depressive disorder,
bipolar disorder, schizophrenia, generalized anxiety disorder, ADHD, and substance use
disorders. Emphasis on evidence-based sequencing, augmentation strategies, and personalized
medicine.
Questions with Rationales
,Page 3 of 132
Section 1: Neurobiology and Neurotransmission (Questions 1–25)
Q1. A 24-year-old neuroscience student is studying the propagation of action potentials along a
myelinated axon. Which structural feature is primarily responsible for the rapid, saltatory
conduction observed in myelinated neurons?
A. Nodes of Ranvier, where myelin is absent and voltage-gated sodium channels are densely
concentrated
B. The myelin sheath itself, which contains voltage-gated sodium channels that depolarize in
sequence
C. Schwann cell nuclei, which generate local electrical currents that propagate the action
potential
D. The axonal microtubules, which physically transport the depolarization wave via dynein-
mediated conduction
Correct Answer: A
Rationale: Saltatory conduction occurs because the myelin sheath electrically insulates
internodal segments, forcing depolarization to regenerate only at the Nodes of Ranvier, where
voltage-gated Na⁺ channels cluster densely. This reduces membrane capacitance and increases
resistance across internodes, producing conduction velocities up to 50× faster than
unmyelinated fibers.
, Page 4 of 132
Q2. A patient with schizophrenia demonstrates prominent positive symptoms that respond to
D2 antagonist antipsychotics. Overactivity in which dopaminergic pathway is most directly
implicated in the pathophysiology of these positive symptoms?
A. Nigrostriatal pathway, projecting from the substantia nigra pars compacta to the dorsal
striatum
B. Mesolimbic pathway, projecting from the ventral tegmental area (VTA) to the nucleus
accumbens and limbic structures
C. Mesocortical pathway, projecting from the VTA to the prefrontal cortex
D. Tuberoinfundibular pathway, projecting from the arcuate nucleus of the hypothalamus to the
pituitary stalk
Correct Answer: B
Rationale: The mesolimbic pathway mediates reward and incentive motivation, and its
hyperactivity is the canonical dopaminergic abnormality underlying positive psychotic
symptoms. The nigrostriatal pathway governs movement, the mesocortical pathway governs
cognition and negative symptoms, and the tuberoinfundibular pathway regulates prolactin
secretion.
Q3. A PMHNP is explaining the mechanism of dopaminergic signaling to a medical student. The
presynaptic neuron releases dopamine into the synaptic cleft, where it binds to postsynaptic
receptors. The primary mechanism for terminating this dopamine signal is:
